首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.

导出 OA

翻译打印收藏纠错

第一作者： Edward A,Motea

第一单位： Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. dboothm@iu.edu eamotea@iu.edu.

作者： Edward A,Motea ^[1] ; Farjana J,Fattah ^[2] ; Ling,Xiao ^[2] ; Luc,Girard ^[3] ; Amy,Rommel ^[4] ; Julio C,Morales ^[5] ; Praveen,Patidar ^[6] ; Yunyun,Zhou ^[7] ; Andrew,Porter ^[8] ; Yang,Xie ^[7] ; John D,Minna ^[3] ; David A,Boothman ^[1]

作者单位： Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. dboothm@iu.edu eamotea@iu.edu. ^[1] Departments of Pharmacology and Radiation Oncology, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. ^[2] Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas. ^[3] Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California. ^[4] Department of Neurosurgery, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma. ^[5] Department of Chemistry, New Mexico Institute of Mining and Technology, Socorro, New Mexico. ^[6] Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas. ^[7] Center for Hematology, Imperial College, London, United Kingdom. ^[8]